WELLESLEY, Mass.--(BUSINESS WIRE)--Point Therapeutics, Inc. (NASDAQ: POTP) announced today that the Company received a staff determination letter on September 12, 2007 from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that trading of Point’s common stock on the Nasdaq Capital market will be suspended at the opening of business on September 21, 2007 unless the Company requests an appeal of the determination.
